From the patients with tumor-adjacent normal samples, just 27% of LUAD, 7% of LUSC and 56% of ER+ tumors had no HLA disruption, while 30.6%, 10.7% and 14.7% of LUAD, LUSC and ER+ tumors exhibited tumor-enriched alternative splicing events. The gene discussed is ESR1; the disease is neoplasm.